0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Expanding Therapy With Long-Acting Antipsychotic Medication in Patients With Schizophrenia

William T. Carpenter Jr, MD1; Robert W. Buchanan, MD1
[+] Author Affiliations
1Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore
JAMA Psychiatry. 2015;72(8):745-746. doi:10.1001/jamapsychiatry.2015.0485.
Text Size: A A A
Published online

Extract

Long-acting injectable (LAI) antipsychotic medications are significantly underused. In light of their documented efficacy for treatment of psychotic symptoms and robust effect on relapse prevention, their relative lack of use is unfortunate. There are several reasons for this therapeutic neglect, including clinical settings where injections are not part of the usual routine; a belief that LAI medications are reserved for acute intervention or for aggressive or nonadherent patients; and the perception of stigmatization associated with their use. Moreover, randomized clinical trials (RCTs) comparing oral antipsychotic medications with LAI medications have often failed to document the expected advantage of assuring adherence with LAI medications because study participant selection often excludes those who are unable to adhere to the study protocol. Finally, physicians routinely overestimate patients’ adherence to oral medication regimens. In this context, 2 articles1,2 in JAMA Psychiatry regarding the use of LAI medications may stimulate reconceptualization of this aspect of pharmacotherapy for treating schizophrenia.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment
Additional Comments to the Editorial
Posted on July 24, 2015
David Hough, MD, Larry Alphs, MD, Alberto Russu, Ph.D
Janssen Research & Development, LLC, Raritan, New Jersey (DH); Janssen Scientific Affairs, LLC, Raritan, NJ (LA); Janssen Research & Development, LLC a Division of Janssen Pharmaceutica NV, Be
Conflict of Interest: All three authors are employees of Janssen

We read with interest the editorial by Carpenter and Buchanan(1) in the June 24, 2015 JAMA Psychiatry.


We agree with the authors that long-acting antipsychotic medications (LAIs) are significantly underused and concur that consideration of LAIs as a treatment option is often overly delayed. Their use could bring value much earlier in the course of illness.

The editorial raises important questions about use of product label-based LAI dosing in clinical practice. The commentators describe their experience with omitting doses of injectable fluphenazine without loss of efficacy. We understand that information provided in product labels must be individualized based on clinical assessment of efficacy and safety considerations. However, given the very long pharmacokinetic half-lives for LAIs (2 weeks to 3 months) this must be done cautiously as steady-state pharmacodynamic effects will take months or, even over a year, as in the case of paliperidone palmitate 3-month (PP3M). Advances in understanding optimal dosing have progressed considerably since the time of fluphenazine decanoate’s approval.

For more recently developed LAIs, robust population pharmacokinetic models were validated in patients (2). Based on this work, stretching the intervals between injections or omitting doses altogether is not recommended as this lowers plasma levels below therapeutic concentrations and may lead to symptomatic relapse. Although the commentators suggest patients may have dose adjustments at regular visits, patients may relapse precipitously, as suggested by a recent comparative study in persons with schizophrenia and a recent history of incarceration (3). For all LAIswe strongly recommend adherence to the dosing recommendations in the label and in particular for PP3M, ensuring that the PP1M dose is well-established before switching to PP3M.


Increasing the interval between injections has not been well studied. The complex and very different pharmacokinetic profiles across LAIs requires careful, often nonintuitive, procedures that would have to be individualized across drugs and patients. We recommend establishing effective doses with oral formulations and using this as a basis for establishing maintenance doses.

The authors rightly point out that the prolonged intervals between treatments with an LAI drug should not reduce essential patient contact. Although patients may require injections as infrequently as every 3 months, monitoring patients on a more frequent basis for efficacy, tolerability, and safety is desirable. Visits in between injections could be used to address issues other than medication adherence, such as psychosocial therapies, vocational rehabilitation, cognitive remediation, or substance abuse treatment.

REFERENCES:
1. Carpenter WT, Jr, and Buchanan, RW. Expanding therapy with long-acting antipsychotic medication in patients with schizophrenia. JAMA Psych. 2015; doi: 10.1001/jamapsychiatry.2015.0485
2. Gopal, S; Vermeulen, A; Nandy, P; Ravenstijn, P; Nuamah, I; Buron Vidal, JA; Berwaerts, J; Savitz, A; Hough, D; Samtani, MN. Population pharmacokinetic simulations of dosing windows and missed doses of paliperidone palmitate 3-month formulation in schizophrenia. Poster presentation at: American Psychiatric Association, Toronto, Canada, 16-20 May 2015. Full manuscript submitted: CurrRes MedOpin.
3. Alphs L, Mao L, Rodriguez SC, Hulihan J, Starr HL. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia. JClin Psych. 2014;75(12):1388-1393.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

1,589 Views
2 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Care at the Close of Life: Evidence and Experience
Pharmacologic Management

Care at the Close of Life: Evidence and Experience
Typical Antipsychotic Medications

brightcove.createExperiences();